

## ABSTRACT

Therapeutic compounds of formula (I) wherein X is CH<sub>2</sub> or SO<sub>2</sub>; R<sup>1</sup> is an optionally substituted aryl or heteroaryl ring; R<sup>2</sup> and R<sup>3</sup> are various specified groups, R<sup>4</sup> is a group NHCOR<sup>15</sup>, NHSO<sub>2</sub>R<sup>15</sup> or OCONR<sup>16</sup>R<sup>17</sup> where R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> are various defined groups; and R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R<sup>4</sup> is a group NHCOR<sup>15</sup>, R<sup>15</sup> is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by MCP-1 (monocyte chemoattractant protein-1) or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.